ImageneBio Inc(IMA)

Biotechnology · San Diego, CA

$4.72+0.02 (+0.43%)

Delayed quote: Oct 6, 2026, 2:23 PM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T18:27:03.040Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:03.040Z.

Quote observation: 2026-10-06T18:23:59.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 53,237,352
TTM operating cash flow · period ending 2026-06-30: -57,733,000

FMP input reference: 3f3fe5cfad96663d45aee285232b63282d401ce5a2dce1ebe999e7f7af3a8937

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

IMA Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

IMA Competitors' Price/OCF Ratio

IMA

ImageneBio Inc

Current

Market Cap

$53.24M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALDX

Aldeyra The

vs IMA

Market Cap

$52.73M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RANI

Rani Therapeutics Holdings, Inc.

vs IMA

Market Cap

$53.50M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MDAI

Spectral AI, Inc.

vs IMA

Market Cap

$53.62M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DWTX

Dogwood Therapeutics, Inc.

vs IMA

Market Cap

$52.46M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NMAD

NOMAD Power Solutions, Inc.

vs IMA

Market Cap

$53.15M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BTMD

biote Corp.

vs IMA

Market Cap

$51.83M

Price/OCF Ratio

2.13

TTM Avg

2.08

3Y Avg

4.49

5Y Avg

3.97

ZYBT

Zhengye Biotechnology Holding Limited

vs IMA

Market Cap

$54.50M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EXOZ

eXoZymes, Inc.

vs IMA

Market Cap

$51.42M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TENX

Tenax Therapeutics, Inc.

vs IMA

Market Cap

$51.19M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
ImageneBio Inc (IMA)	$53.24M	N/A	N/A	N/A	N/A
Aldeyra The (ALDX)vs ›	$52.73M	N/A	N/A	N/A	N/A
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$53.50M	N/A	N/A	N/A	N/A
Spectral AI, Inc. (MDAI)vs ›	$53.62M	N/A	N/A	N/A	N/A
Dogwood Therapeutics, Inc. (DWTX)vs ›	$52.46M	N/A	N/A	N/A	N/A
NOMAD Power Solutions, Inc. (NMAD)vs ›	$53.15M	N/A	N/A	N/A	N/A
biote Corp. (BTMD)vs ›	$51.83M	2.13	2.08	4.49	3.97
Zhengye Biotechnology Holding Limited (ZYBT)vs ›	$54.50M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.42M	N/A	N/A	N/A	N/A
Tenax Therapeutics, Inc. (TENX)vs ›	$51.19M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

IMA Price/OCF Ratio Metrics

IMA Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics